



ALS Research Forum e-Newsletter Vol. 198

June 6, 2018

Visit the [ALS Research Forum](#) to read the complete stories featured in this e-newsletter. Friends and colleagues can sign up for the newsletter [here](#). Follow us on [Facebook](#) and [Twitter](#) for the latest updates.

## Conference News

### [ALS-Targeted Antisense Oligonucleotides Make Waves at AAN 2018](#)

Researchers weigh in on antisense oligonucleotide therapies and their potential for ALS going forward at the 2018 meeting of the American Academy of Neurology (AAN 2018) in Los Angeles, California.

### [At AAN, Sights Set on Antisense Therapies for Diseases of the Brain](#)

Two antisense oligonucleotide therapies have hit the market, including one treatment targeting spinal muscular atrophy. At least nine more are in clinical trials for neurologic diseases. And, an emerging approach for C9orf72 ALS could enter the clinic as early as the end of 2018. Check out this article to learn more about antisense oligonucleotide therapies being developed, including the latest results from clinical trials that evaluate their potential efficacy.

### [As RNA Therapies Come of Age, Efficacy Remains Weak](#)

The earlier the intervention, the greater the chance of a benefit, according to the latest results of Phase 3 and open-label extension studies of RNA therapies presented at AAN 2018 in Los Angeles, California.

## Research News

### [ZFAND1 Triggers Proteasomal Clearance of Stress Granules](#)

Researchers may be one step closer to understanding how stress granules are cleared from neurons, a key first step toward developing ALS therapies that may reduce motor neuron toxicity. The study, led by **Alexander Buchberger** at the University of Würzburg, Germany, found that the protein ZFAND1 recruited the 26S proteasome to stress granules, and the organelles were subsequently removed by autophagy - at least in cultured human cells. The findings appeared online May 24 in *Molecular Cell*.

Check out [our website](#) to read more of the latest research advances in ALS.

## Funding Opportunities:

June 2018

[ALS Canada Project Grant Program](#). ALS Canada. Application due by **June 8, 2018**.

[TREAT ALS Clinical Management Grant](#). Abstracts due by **June 11, 2018**.

[Graduate Student Fellowship](#). MND Australia/NHMRC. Application due by **June 13, 2018**.

[Research Grants](#). Muscular Dystrophy Association. LOI due by **June 15, 2018**.

[Eppendorf & Science Prize for Neurobiology](#). Application due by **June 15, 2018**.

[Innovation Grants to Nurture Initial Translational Efforts \(IGNITE\)](#). Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery. NINDS. Application due by **June 19, 2018**.

[Scientific Innovations Award](#). Brain Research Foundation. LOI due by **June 22, 2018**.

[ALSRP Therapeutic Development Award](#). Application due by **June 22, 2018**.

[ALSRP Therapeutic Idea Award](#). Application due by **June 22, 2018**.

[Roger de Spoelberch Prize](#). Roger de Spoelberch Foundation. Focus: basic and clinical neurodegenerative disease research. Application due before June 30, 2018.

### **July 2018**

**NEW!** [Research Grants](#). AFM-Téléthon. For ALS, priority is given to developing therapies. Researchers across the globe are invited to apply. Applications due: July 3, 2018.

**NEW!** [Research Grants \(Clinical Care and Management\)](#). Funding priorities include clinical outcome measures and telemedicine. AFM-Téléthon. Researchers across the globe are invited to apply. Applications due: July 3, 2018.

[Brain Health and Cognitive Impairment Initiative](#). AHA and Paul G. Allen Frontiers Group. Application due by July 6, 2018.

[Nonclinical and Early-Phase Clinical Development for Biologics](#). NINDS. Funding focus: IND-enabling studies and phase 1 clinical trials. Application due by July 18, 2018.

[Harrington Rare Disease Scholar Award](#). Takeda Pharmaceutical Company. Application due by July 19, 2018.

### **August 2018**

**NEW!** [Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases](#). NINDS. Funding focus: clinical outcome measures and biomarkers. Application due by August 17, 2018.

**NEW!** [Postdoctoral Fellowships](#). AFM-Téléthon. Researchers across the globe are invited to apply. Applications due: August 28, 2018.

**NEW!** [Clinical Research Fellowships](#). AFM-Téléthon. Researchers across the globe are invited to apply. Applications due: August 28, 2018.

**NEW!** [John Templeton Foundation](#). Funding priorities include basic and translational epigenetics/genetics research. Online inquiries must be submitted by August 31, 2018.

**NEW!** [Betty Laidlaw MND Research Prize](#). MND Australia. Application due by August 31, 2018. (Funding call opens in June.)

**NEW!** [Research Grants](#). MND Australia. Application due by August 31, 2018. (Funding call opens in June.)

**The following awards accept applications at any time on a rolling basis.**

[Early Phase Clinical Trials: Canada. Weston Brain Institute](#). Funding priorities include FTD.

[High Throughput Sequencing and Genotyping Resource Access](#). NIH.

[Human Clinical Trials Grant](#). Muscular Dystrophy Association.

[Wellcome Trust Innovator Award \(UK\)](#). Funding focus: development of diagnostics and repurposed medicines for neurological disorders including rare diseases.

Check out our [updated list](#) of grants and awards.

---

### Job Opportunities:

[Professor \(Open-Rank\), Neuroscience](#). University of North Carolina. Chapel Hill, NC.  
[Professor, Computational Neuroscience](#). Université de Montréal. Montréal, Canada.  
[Assistant or Associate Professor, Neurology](#). Columbia University. New York, NY.  
[Assistant Professor, Neurological Disorders](#). Hamad bin Khalifa University. Doha, Qatar.  
[Associate or Full Professor, Molecular Imaging](#). Weill Cornell Medical College. New York, NY.  
[Associate or Full Professor \(Animal Disease Models\)](#). Nanjing University. Nanjing, China.  
[Director, Therapeutic Development](#). University of PA School of Medicine. Philadelphia, PA.  
[Postdoctoral Fellow, Lloyd Lab](#). Johns Hopkins University. Baltimore, MD.

[Director, Antibody Discovery](#). Voyager Therapeutics. Cambridge, MA.  
[Director, Neurodegenerative Research](#). Servier Group. Croissy-sur-Seine, France.  
[Postdoctoral Fellow, ALS](#). Sanofi. Framingham, MA.  
[Research Associate](#). Blue Rock Therapeutics. New York, NY.

Hiring someone onto your team? Contact us to add your listing to [our updated job board](#): [ALSjobs@prize4life.org](mailto:ALSjobs@prize4life.org).

[Full List of Job Opportunities >>](#)

---

### Upcoming Meetings:

Are you studying the potential role of the microbiome in ALS? Abstracts are due on June 24 for the upcoming EMBO Symposium on the [Human Microbiome](#).

#### June 2018

June 17-21, 2018. Keystone, Colorado. [Advances in Neurodegenerative Disease Research and Therapy](#).

June 20-22, 2018. Oxford, England. [ENCALS 2018](#).

June 22-23, 2018. Oxford, England. [TRICALS 2018](#).

#### July 2018

July 6-10, 2018. Vienna, Austria. [International Congress on Neuromuscular Diseases](#).

July 7-11, 2018. Berlin, Germany. [FENS Forum of Neuroscience](#).

July 19-23, 2018. Cold Spring Harbor, NY. [Glia In Health And Disease](#).

July 20-21, 2018. Seoul, South Korea. [International Meeting of the Pan-Asian Consortium for Treatment and Research in ALS](#).

#### August 2018

August 5-10, 2018. Castelldefels, Spain. GRC: [The Role of Innate Immunity, Glia, Neurons, and the Blood-Brain Barrier in the Pathogenesis](#). Abstracts due: July 8, 2018.

Organizing an ALS meeting? Contact us to add your conference to [our updated calendar](#): [ALSmeetings@prize4life.org](mailto:ALSmeetings@prize4life.org).

[Full List of Upcoming Meetings>>](#)

---

The National  
Amyotrophic  
Lateral Sclerosis  
(ALS) Registry



It's Here!

www.cdc.gov/als  
(800) 232-4636



Working with ALS Mice

Click to Download PDF

[Download the Working  
with ALS Mice Manual  
Here](#)

STAY CONNECTED:

